Clinical Trials Logo

Clinical Trial Summary

It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders. Their assessment is therefore essential, particularly in order to propose early and adapted care. However, this assessment remains limited today. A new serious game-type test, REALSoCog, has been developed to address the shortcomings of current tools and to highlight disturbances in social behaviors. The latter are not always observed in consultation although they are often reported by caregivers. The objective of this research is therefore to validate the REALSoCog task in a pathological population (currently being standardized in the general population: CER-U, IRB N°: 00012020-115). The clinical interest of this task will be tested with a group of patients suffering from a neurodegenerative disease (Alzheimer's disease (AD), dementia with Lewy bodies (DCL), fronto-temporal lobar degeneration (FTD)) in order to assess its sensitivity and specificity in the detection of social-cognitive disturbances, and in particular in terms of social behaviors (detection of social behavioral disorders reported in daily life). The objective is also to document the socio-cognitive profiles in the mentioned diseases thanks to a more ecological test, and to better understand the links between socio-cognitive processes on the one hand, and individual characteristics on the other hand (e.g. mood and social participation).


Clinical Trial Description

It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders. Their assessment is therefore essential, particularly in order to propose early and adapted care. However, this assessment remains limited today. A new serious game-type test, REALSoCog, has been developed to address the shortcomings of current tools and to highlight disturbances in social behaviors. The latter are not always observed in consultation although they are often reported by caregivers. The objective of this research is therefore to validate the REALSoCog task in a pathological population (currently being standardized in the general population: CER-U, IRB N°: 00012020-115). The clinical interest of this task will be tested with a group of patients suffering from a neurodegenerative disease (Alzheimer's disease (AD), dementia with Lewy bodies (DCL), fronto-temporal lobar degeneration (FTD)) in order to assess its sensitivity and specificity in the detection of social-cognitive disturbances, and in particular in terms of social behaviors (detection of social behavioral disorders reported in daily life). The objective is also to document the socio-cognitive profiles in the mentioned diseases thanks to a more ecological test, and to better understand the links between socio-cognitive processes on the one hand, and individual characteristics on the other hand (e.g. mood and social participation). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05558709
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Marc VERNY, Pr
Phone 01 42 16 03 12
Email marc.verny@aphp.fr
Status Not yet recruiting
Phase N/A
Start date June 1, 2024
Completion date June 1, 2028

See also
  Status Clinical Trial Phase
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT02593318 - Trial of Oxaloacetate in Alzheimer's Disease (TOAD) Phase 1
Completed NCT02681172 - Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Phase 4
Completed NCT02264899 - MEMENTO-VAScular COmponents of Dementia N/A
Completed NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Phase 0
Recruiting NCT04570761 - Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study N/A
Not yet recruiting NCT05592678 - δ in Dementia Clinical Trials Phase 2/Phase 3
Recruiting NCT05059158 - Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Recruiting NCT02832921 - Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk N/A
Completed NCT02370524 - Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease Phase 1
Completed NCT01780519 - The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms Phase 1
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Completed NCT03802162 - A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 Phase 1
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Recruiting NCT05291234 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease Phase 2
Active, not recruiting NCT05771428 - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease Phase 2
Recruiting NCT06114745 - A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Phase 1